What should I do if I am resistant to Obinutuzumab?

Follicular lymphoma often relapses and is difficult to cure. Obinutuzumab is a humanized glycoengineered type II anti-CD20 antibody. Its mode of action includes induction of antibody-dependent cellular cytotoxicity, antibody-dependent phagocytosis and direct cell death. There is no evidence of the effectiveness of rechallenge with otuzumab in patients who have previously received otuzumab.

Clinical data demonstrate the efficacy of otuzumab against CD20-positive non-Hodgkin lymphoma (NHL) cells that are resistant to direct cell death induced by otuzumab. The data showed that, across all drug-resistant cells, several combinations of otuzumab plus chemotherapy exerted a superadditive effect in the treatment of patients with follicular lymphoma. The results showed that doxorubicin enhanced the growth inhibitory effect of otuzumab through a caspase-dependent mechanism in drug-resistant cells; the combination of otuzumab plus prednisolone enhanced the growth inhibition by increasing cell death and further enhanced the growth inhibition by inducing G0–G1 arrest in drug-resistant cells. Furthermore, in vivo, resistant cells retained their resistance to direct cell death induced by otuzumab, and these combined effects were also confirmed in otuzumab-refractory cells.

The original drug of Otuzumab has been launched in China and has entered the scope of medical insurance, but it is only reimbursed for patients who meet the indications. Specifications The price of 1000mg (40ml)*1 bottle may be around 9,000 yuan, which is a strictly controlled drug. The price of the Turkish version of Otuzumab Specifications1000mg/40ml per box listed overseas may be around RMB 10,000 (the price may fluctuate due to the exchange rate). The ingredients of the original drugs sold domestically and abroad are basically the same. There is currently no generic version of Otuzumab produced and launched. For more drug information and specific prices, please consult the medical consultant of Yaode.